<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03726125</url>
  </required_header>
  <id_info>
    <org_study_id>16939</org_study_id>
    <secondary_id>I9R-MC-BSDA</secondary_id>
    <nct_id>NCT03726125</nct_id>
  </id_info>
  <brief_title>A Study of LY3374849 in Healthy Participants</brief_title>
  <official_title>A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Glucodynamic Effects of LY3374849 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to evaluate the safety and tolerability of the study drug known as
      LY3374849, when given as an injection to healthy participants.

      The study will also investigate how quickly the body absorbs and gets rid of LY3374849 and
      how it affects the levels of blood sugar in comparison to insulin degludec, after a single
      dose is given by injection under the skin and directly into a vein.

      Participation in this study includes screening, which is required within 28 days before start
      of study and a follow up at least 28 days after receiving the last dose of study drug.

      This study has 3 parts:

        -  Participants in Part A will complete 1 study period (approximately 1 week).

        -  Participants in Part B will complete 3 study periods (approximately 3 weeks).

        -  Participants in Part C will complete 2 study periods (approximately 2 weeks).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parts B and C added per protocol amendment, approved in April 2019.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2018</start_date>
  <completion_date type="Actual">September 27, 2019</completion_date>
  <primary_completion_date type="Actual">September 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parts B and C are crossover design.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind in Part A. Open label in Parts B and C.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to study completion (estimated at 11 weeks)</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucodynamics: Total Amount of Glucose Infused (Gtot)</measure>
    <time_frame>Baseline up to 36 hours post-dose for each study arm</time_frame>
    <description>Glucodynamics: Gtot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3374849</measure>
    <time_frame>Baseline at predose through 6 days post-dose for each study arm</time_frame>
    <description>Pharmacokinetics: AUC of LY3374849</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3374849 - SC (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous (SC) dose of LY3374849</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Degludec - SC (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC dose of insulin degludec</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3374849 - SC (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY3374849 administered SC in up to three of three study periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3374849 - IV (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY3374849 administered intravenously (IV) in up to one of three study periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3374849 - IV (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose of LY3374849 in one of two study periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Degludec - IV (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose of insulin degludec in one of two study periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3374849 - SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3374849 - SC (Part A)</arm_group_label>
    <arm_group_label>LY3374849 - SC (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Degludec - SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Insulin Degludec - SC (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3374849 - IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3374849 - IV (Part B)</arm_group_label>
    <arm_group_label>LY3374849 - IV (Part C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Degludec - IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Insulin Degludec - IV (Part C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or a female who cannot become pregnant

          -  Have a body mass index (BMI) of at least 18 kilogram per square meter (kg/mÂ²)

          -  Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine
             laboratory test results that are acceptable for the study

          -  Have veins suitable for easy blood collection and glucose solution infusion

        Exclusion Criteria:

          -  Are currently participating in or completed a clinical trial within the last 30 days
             or any other type of medical research judged to be incompatible with this study

          -  Had donated or had blood loss of more than 450 milliliters (mL) within the last 3
             months

          -  Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week
             (female)

          -  Smoke more than 10 cigarettes per day

          -  Are infected with hepatitis B or human immunodeficiency virus (HIV)

          -  Have a history of allergies or reactions to more than one drug, or significant severe
             drug allergy

          -  Are taking illegal drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lilly Centre for Clinical Pharmacology</name>
      <address>
        <city>Singapore</city>
        <zip>138623</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>October 15, 2019</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2018</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

